<DOC>
	<DOCNO>NCT02325362</DOCNO>
	<brief_summary>The purpose study demonstrate Miglustat restore function cystic fibrosis transmembrane conductance regulator ( CFTR ) adult patient cystic fibrosis homozygous F508del mutation .</brief_summary>
	<brief_title>Effect Miglustat Nasal Potential Difference Patients With Cystic Fibrosis Homozygous F508del Mutation</brief_title>
	<detailed_description>The aim study : 1 . To determine whether Miglustat restore function CFTR protein adult patient cystic fibrosis homozygous F508del mutation 2 . To evaluate safety , tolerability pharmacokinetics Miglustat adult patient cystic fibrosis homozygous F508del mutation . 3 . To investigate pharmacokinetic-pharmacodynamic Miglustat adult patient cystic fibrosis homozygous F508del mutation .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Miglustat</mesh_term>
	<mesh_term>1-Deoxynojirimycin</mesh_term>
	<criteria>Inclusion criterion screen visit ( Visit 1 ) : Aged 18 year old Male female Women childbearing potential must : negative serum pregnancy test Visit 1 agree use Visit 1 3 month last study drug intake reliable method contraception Male patient accept duration study 3 month thereafter use condom Homozygous F508del mutation confirm genetic testing Sweat chloride ≥ 60 mmol/L Basal nasal potential difference ( NPD ) ≤ 30.0 mV ( equal electrically negative 30.0 mV ) total chloride secretion ( TCS ) ≥ 5.0 mV least one nostril . However , possible analyze nostril , total chloride secretion ( TCS ) ≥ 5.0 mV ( equal electrically positive 5.0 mV ) nostril . FEV1 ≥ 25 % predict Able comply protocol requirement Signed informed consent prior studymandated procedure Inclusion criterion randomization visit ( Visit 2 ) : Women childbearing potential must negative urine pregnancy test Basal nasal potential difference ( NPD ) ≤ 30.0 mV ( equal electrically negative 30.0 mV ) total chloride secretion ( TCS ) ≥ 5.0 mV least one nostril . However , possible analyze nostril , total chloride secretion ( TCS ) ≥ 5.0 mV ( equal electrically positive 5.0 mV ) nostril . Any condition prohibit correct measurement NPD upper respiratory tract infection Acute upper low respiratory tract infection require antibiotic intervention within 2 week screen Lung transplant recipient patient lung transplant wait list Any modification regular treatment ( new treatment initiate discontinue treatment ) modification dose within 2 week prior start Period 1 Moderate/Severe renal impairment ( creatinine clearance &lt; 70 mL/min per Cockroft Gault ) Systemic corticosteroid ( &gt; 10 mg/day prednisone equivalent ) within 14 day prior screen start study Women breastfeeding , pregnant , plan become pregnant course study History significant lactose intolerance Presence clinically significant diarrhoea ( &gt; 3 liquid stool per day &gt; 7 day ) without definable cause within one month prior screen Any known factor disease might interfere treatment compliance , study conduct interpretation result drug alcohol dependence psychiatric disease Active passive smoking Hypersensitivity Miglustat excipients Planned treatment treatment another investigational drug therapy ( e.g. , gene therapy ) within one month prior randomization Known concomitant lifethreatening disease life expectancy &lt; 12 month Indication Isuprel® ( Isoproterenol ) include heart disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Cystic fibrosis</keyword>
	<keyword>CFTR</keyword>
	<keyword>F508del mutation</keyword>
	<keyword>Miglustat</keyword>
	<keyword>Total Chloride Secretion</keyword>
	<keyword>Nasal Potential Difference</keyword>
</DOC>